Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV).
The agreement looks to expand on each firms’ expertise in reproductive medicine and women’s health, by creating standardised, stable live microbiota-based formulations addressing the vaginal infection.
Common among women of reproductive age, the condition is linked to an increased risk of miscarriage, as well as problems during pregnancy and fertility issues.
“Today’s agreement is an important evolution of our long-standing relationship with Ferring in the field of microbiota-based therapies for the benefit of women's health, including reproduction and pregnancy,” says MyBiotics’ CEO, David Daboush.